WO2014027334A3 - Composition pharmaceutique orale sous forme de microsphères et procédé de préparation - Google Patents

Composition pharmaceutique orale sous forme de microsphères et procédé de préparation Download PDF

Info

Publication number
WO2014027334A3
WO2014027334A3 PCT/IB2013/056690 IB2013056690W WO2014027334A3 WO 2014027334 A3 WO2014027334 A3 WO 2014027334A3 IB 2013056690 W IB2013056690 W IB 2013056690W WO 2014027334 A3 WO2014027334 A3 WO 2014027334A3
Authority
WO
WIPO (PCT)
Prior art keywords
microspheres
preparation
pharmaceutical composition
oral pharmaceutical
composition
Prior art date
Application number
PCT/IB2013/056690
Other languages
English (en)
Spanish (es)
Other versions
WO2014027334A2 (fr
Inventor
Gustavo BARRANCO HERNÁNDEZ
María del Coral LUNA GUIZA
Héctor SENOSIAIN ARROYO
Original Assignee
Laboratorios Senosiain, S.A. De C.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50435594&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2014027334(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Laboratorios Senosiain, S.A. De C.V. filed Critical Laboratorios Senosiain, S.A. De C.V.
Publication of WO2014027334A2 publication Critical patent/WO2014027334A2/fr
Publication of WO2014027334A3 publication Critical patent/WO2014027334A3/fr
Priority to CR20150077A priority Critical patent/CR20150077A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une composition sous forme de microparticules principalement composées de : a) un noyau inerte; b) une couche de principe actif formée par aspersion sur le noyau inerte et c) éventuellement un second revêtement comprenant une ou plusieurs couches de médicament(s) et/ou excipient(s) pharmaceutiquement acceptable(s). Ladite composition est utilisée pour le traitement de maladies résultant d'une rétention d'eau et/ou d'électrolytes excessive, de maladies cardiovasculaires, de maladies rénovasculaires, d'un diabète, de dysfonctionnements endothéliaux, d'une cirrhose, d'une prééclampsie, d'une néphropathie, d'une maladie vasculaire périphérique et d'une hypertension, entre autres.
PCT/IB2013/056690 2012-08-17 2013-08-16 Composition pharmaceutique orale sous forme de microsphères et procédé de préparation WO2014027334A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CR20150077A CR20150077A (es) 2012-08-17 2015-02-13 Composición farmacéutica oral en forma de microesferas y proceso de elaboración

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MXMX/A/2012/009583 2012-08-17
MX2012009583A MX351059B (es) 2012-08-17 2012-08-17 Composicion farmaceutica oral en forma de microesferas y proceso de elaboracion.

Publications (2)

Publication Number Publication Date
WO2014027334A2 WO2014027334A2 (fr) 2014-02-20
WO2014027334A3 true WO2014027334A3 (fr) 2014-04-10

Family

ID=50435594

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/056690 WO2014027334A2 (fr) 2012-08-17 2013-08-16 Composition pharmaceutique orale sous forme de microsphères et procédé de préparation

Country Status (8)

Country Link
CL (1) CL2015000375A1 (fr)
CO (1) CO7310526A2 (fr)
CR (1) CR20150077A (fr)
DO (1) DOP2015000028A (fr)
GT (1) GT201500035A (fr)
MX (1) MX351059B (fr)
PE (1) PE20150710A1 (fr)
WO (1) WO2014027334A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106821996A (zh) * 2017-03-01 2017-06-13 华益药业科技(安徽)有限公司 马来酸依那普利颗粒剂及其制备方法
CN108472257B (zh) * 2015-12-28 2020-12-04 新丰制药株式会社 药物组合制剂

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102153557B1 (ko) 2013-03-27 2020-09-09 에프. 호프만-라 로슈 아게 치료에 대한 반응성을 예측하기 위한 유전 마커
EP3174995B1 (fr) 2014-07-30 2020-08-19 F.Hoffmann-La Roche Ag Marqueurs génétiques pour la prédiction de la réactivité à une thérapie avec un agent d'augmentation de hdl ou d'imitation de hdl
CN104523710B (zh) * 2014-12-30 2018-05-25 石药集团欧意药业有限公司 一种硫酸氢氯吡格雷阿司匹林复合双层片及其制备方法
EP3582777A4 (fr) 2017-02-17 2020-12-23 Unichem Laboratories Ltd Composition pharmaceutique d'apixaban
HRP20240529T1 (hr) * 2018-04-16 2024-07-05 Bristol-Myers Squibb Company Formulacije apiksabana
CN115461043B (zh) * 2020-02-19 2024-09-24 纳米制药解决方案公司 治疗剂纳米颗粒及其制备方法
US11833133B2 (en) * 2020-08-13 2023-12-05 Orient Pharma Co., Ltd. Solid oral pharmaceutical composition
CN113413364A (zh) * 2021-05-31 2021-09-21 辰欣药业股份有限公司 一种依诺肝素钠注射液及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008039052A2 (fr) * 2006-09-25 2008-04-03 ESPINOSA ABDALA, Leopoldo de Jesús Procédé de stabilisation de la famotidine
WO2008045006A1 (fr) * 2006-10-11 2008-04-17 Fako Ilaclari A. S. Formulations de candésartan
WO2009007808A1 (fr) * 2007-07-11 2009-01-15 Laboratorios Senosiain S.A. De C.V. Composition pharmaceutique combinée
US20100092453A1 (en) * 2006-01-27 2010-04-15 Anne Marie Healy Method of producing porous microparticles

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100092453A1 (en) * 2006-01-27 2010-04-15 Anne Marie Healy Method of producing porous microparticles
WO2008039052A2 (fr) * 2006-09-25 2008-04-03 ESPINOSA ABDALA, Leopoldo de Jesús Procédé de stabilisation de la famotidine
WO2008045006A1 (fr) * 2006-10-11 2008-04-17 Fako Ilaclari A. S. Formulations de candésartan
WO2009007808A1 (fr) * 2007-07-11 2009-01-15 Laboratorios Senosiain S.A. De C.V. Composition pharmaceutique combinée

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108472257B (zh) * 2015-12-28 2020-12-04 新丰制药株式会社 药物组合制剂
CN106821996A (zh) * 2017-03-01 2017-06-13 华益药业科技(安徽)有限公司 马来酸依那普利颗粒剂及其制备方法

Also Published As

Publication number Publication date
CO7310526A2 (es) 2015-06-30
CR20150077A (es) 2015-05-13
CL2015000375A1 (es) 2015-07-10
MX351059B (es) 2017-09-29
GT201500035A (es) 2017-10-24
DOP2015000028A (es) 2015-03-15
PE20150710A1 (es) 2015-05-28
WO2014027334A2 (fr) 2014-02-20
MX2012009583A (es) 2014-02-26

Similar Documents

Publication Publication Date Title
WO2014027334A3 (fr) Composition pharmaceutique orale sous forme de microsphères et procédé de préparation
WO2008146178A3 (fr) Nouvelle forme posologique de comprimé
WO2011039768A3 (fr) Compositions pharmaceutiques pour réduire une libération massive induite par l'alcool
WO2011099832A3 (fr) Nouveau composé de benzimidazole, son procédé de préparation et composition pharmaceutique le contenant
CL2013003331A1 (es) Tableta de liberacion inmediata a prueba de alteracion que comprende (i) una matriz, y (ii) una pluralidad de material particulado, que comprende un opiaceo y un polimero de oxido de polietileno de mas de 20.000 g/mol, donde el multiparticulado forma una fase discontinua dentro de la matriz.
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
WO2009063222A3 (fr) Compositions solides
WO2011123836A3 (fr) Formulations pharmaceutiques pour le traitement de vessie hyperactive
BRPI0910758A2 (pt) composição sólida termoestável, composição farmacêutica, processos para a preparação de uma composição sólida termoestável e de uma composição farmacêutica, método para melhorar a biodisponibilidade de um ingrediente farmaceuticamente ativo, e, produto
CL2013002504A1 (es) Preparacion farmaceutica solida recubierta que comprende a lo menos un ingrediente activo y porque el recubrimiento tiene un espesor de 0,1 a 100nm, de preferencia de 0,3 a 50 nm y mas preferentemente de 0,5 a 35 nm; y su metodo de preparacion
LT2808325T (lt) Pakeistieji azolai, antivirusinis aktyvus ingredientas, farmacinė kompozicija, jų gavimo ir panaudojimo būdas
WO2009059701A3 (fr) Comprimés à libération prolongée contenant de l'hydromorphone
WO2011140446A3 (fr) Formulations pharmaceutiques
WO2012064150A3 (fr) Composition comprenant des dérivés de benpropérine en tant que principes actifs pour la prévention et le traitement de maladies associées à l'angiogenèse
WO2012162439A3 (fr) Compositions comprenant de l'acide fusidique et leurs emballages
WO2015003479A3 (fr) Pastille solide administrée par voie orale pour nourrissons et enfants et procédé de préparation
EP2796450A4 (fr) Dérivés 6-aminopyridine-3-ol ou leurs sels pharmaceutiquement acceptables, et composition pharmaceutique contenant ces dérivés ou ces sels comme principes actifs pour la prévention ou le traitement des maladies provoquées par l'angiogenèse
WO2015038552A3 (fr) Formulation d'aspirine pour une efficacité améliorée
WO2012145575A3 (fr) Thérapie pour la leucémie
PH12015500653B1 (en) Combination drug comprising gemigliptin and metformin, and method for the preparation thereof
WO2012085249A3 (fr) Formes pharmaceutiques orales homogènes comprenant de la lercanidipine et de l'énalapril ou leurs sels pharmaceutiquement acceptables
EA201590474A1 (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ОСНОВЕ КОМПОЗИТНЫХ КАПСУЛ, ВКЛЮЧАЮЩИХ ИРБЕСАРТАН И ИНГИБИТОР ГМГ-КоА РЕДУКТАЗЫ
WO2014141295A3 (fr) Traitement et prophylaxie de maladies rénales
WO2012077968A3 (fr) Formulation complexe contenant de l'hydrochlorure de lercanidipine et du valsartan et son procédé de préparation
WO2014085494A8 (fr) Thérapeutique combinée et méthodes de traitement de maladies neurodégénératives et autres

Legal Events

Date Code Title Description
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: CR2015-000077

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 000210-2015

Country of ref document: PE

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2015000375

Country of ref document: CL

WWE Wipo information: entry into national phase

Ref document number: 15048826

Country of ref document: CO

122 Ep: pct application non-entry in european phase

Ref document number: 13872270

Country of ref document: EP

Kind code of ref document: A2